Search results for "DOSE"
12:38

Franklin Templeton: The friendly winds of encryption between the United States and Asia may inject a strong dose of confidence into the European Union.

Gate News bot reported that Catriona Kellas, the Head of International Legal Projects at Franklin Templeton, stated at the DigiAssets 2025 conference that the EU could potentially become a "flyover zone" for Crypto Assets between the US and Asia due to the legislative pace lagging behind that of the US and Asia. "This technology does carry risks, and jurisdictions that may have been at the forefront a few years ago can easily fall behind if the legislative process takes too long," she said, noting that "other jurisdictions" have adopted more flexible policies in the Crypto Assets space. She indicated that the European Commission seems to have recognized this, recalling a recent conversation where "they mentioned a word I had never heard before, which is 'competition'." "They certainly asked the right questions," Kellas added, stating that the rumors surrounding "MiCA 2" (the updated version of the Markets in Crypto Assets regulation) are "far from rumors", with the legislation set to take effect in June 2023. "It may be coming soon," she added.
More
04:21

Hanyu Pharmaceutical: The enrollment of all subjects in the Phase III clinical trial for the weight loss indication of Semaglutide Injection has been completed.

Jin10 data reported on June 12th that Hanyu Pharmaceutical stated on the interactive platform that the company's Semaglutide injection is being submitted for listing under Category 2. The weight loss indication completed the enrollment of all trial subjects for Phase III clinical trials in January this year and is currently in the follow-up phase, with the project having entered the dose maintenance period. After the completion of the future Phase III clinical trials, the company will organize and improve the clinical trial data according to relevant regulatory requirements and submit a listing application.
More
11:34

Research on the weight loss drug CagriSema by Noor and Noord

On February 5th, Jinshi Data reported that Novonordisk (NVO.N) stated on Wednesday that its new trial of the next generation obesity drug CagriSema will focus on dose escalation and the duration of the trial to further demonstrate the potential of the drug. Last December, the data of this drug disappointed the market, leading to a 27% drop in the company's stock price, one of the largest single-day declines among European companies. Jorgensen, the CEO of the company, said that the company has confidence in the biological characteristics of this drug and is encouraged by what they have seen in the data.
More
05:02

Sinopharm COVID-19 vaccine price confusion: wrong price reported yesterday, no actual price decrease

On August 15th, Jinshi Data reported that the Anhui Provincial Medical Centralized Procurement Platform announced the latest procurement catalog for the Anhui Province's 2024 coronavirus vaccine and some non-immunization plan vaccines. Watson Biotechnology's OmicronXBB.1.5, a new coronavirus variant bead mRNA vaccine, was included in the procurement catalog at a price of 278 yuan per dose. The previous day's price for this product was 94 yuan per dose, a decrease of about 70% compared to the price announced by Shandong. Watson Biotechnology confirmed that the price announced by Anhui on the previous day was incorrect, and the latest correct price is consistent with the price in Shandong, and there has been no price reduction.
13:17

Watson Biotech's COVID-19 mRNA vaccine dropped in price by over 70% in one day

The Anhui Provincial Medical Procurement Platform issued a notice to include the Watson Biological Omicron XBB.1.5 mRNA vaccine (variant bead) at a price of 94 yuan/dose in the procurement catalog, a decrease of 71.94% compared to the proposed listing price of 278 yuan/dose on the Shandong Provincial Public Resource Trading Platform.
More
11:35

Sage terminates a drug development, plunges in premarket

On July 24th, Jinshi Data, Sage Therapeutics and Biogen announced the termination of the development of a proposed drug for the treatment of essential tremor of the nervous system, as the drug failed in a mid-term study. Sage and Biogen stated on Wednesday that a Phase II dose-ranging study showed no statistically significant differences in the change from baseline to day 91 in any dose of the investigational drug SAGE-324 compared to placebo. Sage Therapeutics' stock fell 28% pre-market.
  • 1
03:10
Polygon in Danger: Will MATIC Rebound or Fall into a Sub-$1 Slump? Polygon (MATIC), Ethereum's high-speed scaling solution, has been on a rollercoaster ride this month. After a sharp correction in which the MATIC price falls by more than 20%, the surge in the last 24 hours has injected a dose of optimism into the market. But is this a sign of a full recovery, or is it a temporary relief before a further decline? The data paints a sobering picture. MATIC's ranking among the top 20 Crypto Assets has been steadily declining and is currently ranked 18th. This decline coincided with a significant price fall, with MATIC losing more than a quarter of its value in the last 30 days. Analysts such as World of Charts point to the descending channel pattern on the MATIC daily chart, which is a classic indicator for fall trends. For a real price recovery, MATIC needs to overcome a key obstacle: the $0.77 resistance level. A break above this could trigger a bull market to the $1 level, but it won't be easy to pump up. The past 24 hours have given a glimmer of hope to Polygon's longest. Token price surged 5%, briefly breaking the $0.74 mark. This rise coincided with an improvement in the MVRV ratio, which indicates an increase in the number of profitable MATIC investors. In addition, the bullish crossover of the MACD indicator suggests that buying pressure may increase. Beneath the surface, however, some worrying trends remain. Despite the recent price pump, the data shows that Polygon is under significant selling pressure. A significant increase in exchange inflows indicates that investors are transferring Tokens to exchanges, which is often a precursor to a sell-off. This trend is further confirmed by an increase in the supply of MATIC within the exchanges and a decrease in the supply outside the exchanges. Despite the silver lining of the MACD, other technical indicators remain falling. Bollinger Bands indicate Fluctuation dropping, which could be a sign of consolidation before a breakout or price falls further. Both the Money Flow Index (MFI) and the Chaikin Money Flow Index (CMF) fall downward, potentially signaling the end of a short-lived Bull Market Rebound. While Polygon's technological outlook remains uncertain, a complete reversal is not out of the question. Continued positive developments within the Polygon ecosystem, coupled with a broader market recovery, are likely to drive MATIC pump. However, overcoming selling pressure and technical resistance levels is essential for a sustained Bull Market. Investors should exercise caution and keep a close eye on market developments before making any investment decisions. (Source: Christian Encila)
ETH-1.78%
  • 1
03:12
The outlook for Dogecoin is promising: the total volume of transactions over the past week has reached a staggering $4.5 billion Top analysts have made a bold statement whose bold assertions have shaken the foundations of the market – Dogecoin's journey to $1 is not just a speculative exercise, but an obvious prospect in the current market cycle. Amid the hustle and bustle of market volatility, their confidence adds a new perspective to Dogecoin's narrative. Important market data reveals the intricate dance between Dogecoin and Bitcoin, with a price correlation of up to 0.95. This digital symbiosis highlights the impact of broader cryptocurrency trends on the movement of the Dogecoin market. Despite the ups and downs of the market landscape, Dogecoin has an impressive trading volume of over $100,000 and a staggering $4.5 billion in total transactions over the past week. A closer look at Dogecoin's exchanges gives an idea of its current battleground. The detailed breakdown of Dogecoin addresses reveals a subtle picture – 58% of addresses are "inside the money" and enjoy profits, while 34% of addresses find themselves "out of money" and suffer losses. In the history of cryptocurrency, Dogecoin's trajectory has been like a crazy journey, marked by dizzying highs and sudden drops. At the beginning of 2021, the rise of meme coins, fueled by celebrity endorsements, hit a roadblock, as Elon Musk easily dismissed Dogecoin as a "hustle" in Saturday Night Live. According to the data, since then, Dogecoin has struggled to regain its former glory, falling 70% from its all-time high. Ali Martinez, a crypto personality himself with 50,700 fanatical followers on the X social media platform, is adding fuel to Dogecoin's fire. Martinez pointed to historical patterns, predicting that Dogecoin could spike and expecting Dogecoin to hit the $1 mark in mid-April. His chart depicts Dogecoin's meteoric rise, reminiscent of the crypto boom of 2017 and 2021, injecting a dose of enthusiasm into the market where Dogecoin is currently priced at $0.167. With 209,800 followers, the mysterious altcoin Sherpa has attracted attention and joined the ranks of optimism. Sherpa foresees Dogecoin soaring to $1, pointing to its enduring appeal in meme culture and the influential support of Elon Musk. (Source: Christian Encila)
DOGE3.25%
BTC-0.6%
ALI0.2%
MEME-2.64%
  • 1
14:44
PANews News on October 18, according to Blockworks, FTX founder Sam Bankman-Fried (SBF) trial has entered the final stage, the prosecution has only a few witnesses, and most of the important people have now testified. U.S. prosecutors told the court that they were a little ahead of schedule and could conclude the case as soon as next week (note that the trial will be suspended on Friday and will not continue until next Thursday). However, it is unclear what action the defense will take or whether the SBF will appear in court. SBF defense attorney Mark Cohen told the judge and prosecutors Tuesday: "We are still considering whether to bring a lawsuit, and the nature of the lawsuit." But I still think that if we file a lawsuit, it will not take more than a week and a half at most. ” Previously, SBF applied to increase the dose of drugs during the trial to ensure its ability to testify. Starting Thursday, SBF will have access to increased doses of the drug, and the defense will assess whether it can appear in court.
  • 1
01:01
PANews reported on October 16 that the lawyer representing FTX founder Sam Bankman-Fried (SBF) submitted an application to the court on Sunday evening local time, expressing the hope that SBF can be allowed to increase the dose of Adderall's drug during the trial, noting that this may affect SBF's ability to testify. It is reported that Adela is a neurostimulant drug, because it can increase people's alertness, temporarily reduce fatigue and increase aggression, mostly used to treat attention deficit and hyperactivity disorder (ADHD) and narcolepsy.
00:54
On October 16, the SBF's lawyer submitted an application to the court on Sunday evening local time, expressing the hope that the SBF would be allowed to increase the dose of Adderall's drug during the trial, and pointed out that this may affect the SBF's ability to testify. Note: Adra is a neurostimulant drug, because it can increase people's alertness, temporarily reduce fatigue and increase aggression, mostly used to treat attention deficit and hyperactivity disorder (ADHD) and narcolepsy.
Load More
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)